MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Neoleukin Therapeutics Operating Income 2011-2026 | NLTX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Neoleukin Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -55.6 M | -56.5 M | -60.7 M | -33.7 M | -71 M | -32.6 M | -51.1 M | -37.6 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -32.6 M | -71 M | -49.9 M |
Quarterly Operating Income Neoleukin Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -23.8 M | -26.1 M | -25.9 M | - | -22.2 M | -20.1 M | -18.8 M | - | -15.2 M | -12.6 M | -15.1 M | - | -13.6 M | -15.9 M | -15.4 M | - | -15.5 M | -15.1 M | -14.9 M | - | -2.25 M | -9.77 M | -9.07 M | - | -59.5 M | -428 K | - | - | -15.2 M | 2.69 M | - | - | -12.1 M | -14 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.69 M | -59.5 M | -16.2 M |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.3 | -0.3 % | $ 86.3 M |  Canada |
 |
China Pharma Holdings
CPHI
|
-4.59 M | $ 0.63 | - | $ 11 M |  China |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | - | - | $ 2.06 B |  France |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 8.04 | -0.12 % | $ 412 M | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 3.18 | 4.1 % | $ 44.7 M | USA |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 22.82 | 0.75 % | $ 1.06 B | USA |
 |
Bausch Health Companies
BHC
|
963 M | $ 4.97 | -2.55 % | $ 1.81 B | Canada |
 |
Harrow Health
HROW
|
30.5 M | $ 35.03 | 3.03 % | $ 1.29 B | USA |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
Evolus
EOLS
|
-32.7 M | $ 4.43 | -5.45 % | $ 286 M | USA |
 |
Rockwell Medical
RMTI
|
-6.67 M | $ 1.04 | 1.96 % | $ 24.3 M | USA |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 0.87 | -0.29 % | $ 43.4 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Solid Biosciences
SLDB
|
-179 M | $ 6.69 | -6.3 % | $ 585 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.36 | -0.37 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 2.34 | -8.24 % | $ 2.9 M | USA |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 6.01 | 2.56 % | $ 237 M | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.36 | 0.01 % | $ 402 M | Canada |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 6.57 | 1.86 % | $ 4.06 B | Canada |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
23.6 M | - | - | $ 5.07 M | USA |
 |
TherapeuticsMD
TXMD
|
-8.52 M | $ 2.28 | -1.2 % | $ 23.8 M | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
Veru
VERU
|
-36.9 M | $ 2.28 | -0.87 % | $ 308 M | USA |
 |
Viatris
VTRS
|
766 M | $ 13.43 | 1.02 % | $ 16.1 B | USA |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
cbdMD
YCBD
|
-3.32 M | $ 0.78 | 1.3 % | $ 3.36 M | USA |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 2.43 | -1.62 % | $ 320 M | USA |
 |
Perrigo Company plc
PRGO
|
-1.12 B | $ 9.65 | 0.89 % | $ 1.34 B | USA |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 0.94 | -2.32 % | $ 101 M | Canada |
 |
Assertio Holdings
ASRT
|
-21.5 M | $ 15.95 | 13.93 % | $ 102 M | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M | USA |